Cuprina Holdings (Cayman) LTD Annual Report - How They Did This Year

I’ve put together this guide to help you understand Cuprina Holdings’ performance over the past year. My goal is to turn complex filing data into plain English so you can decide if this company fits your investment goals.

1. What does this company do?

Cuprina is a medical technology company specializing in Maggot Debridement Therapy (MDT)—a biological treatment for hard-to-heal wounds—and a line of skincare products. Their core business involves producing medical-grade larvae to clean dead tissue from wounds that resist standard treatments. They serve hospitals, clinics, and specialized medical practitioners.

2. Financial performance: The "Growth" Phase

Cuprina is currently in a building phase. Because they are scaling up manufacturing and regulatory work, they aren't profitable yet.

• Profit/Loss: Their loss grew from S$1.5M in 2024 to S$4.67M (approx. US$3.63M) in 2025. This was primarily driven by higher administrative costs and expenses related to entering international markets.
• Cash Burn: The company is spending heavily to grow. In 2025, they used S$9.13M (US$7.1M) in cash for operations, a sharp increase from the S$1.24M used in 2024, reflecting heavy investment in research, development, and their IPO.

3. Major wins and challenges

• The IPO Milestone: Their April 2025 IPO provided a vital cash boost. This stabilized the balance sheet, moving them from a deficit in 2024 to holding net current assets of S$4.2M (US$3.27M) by the end of 2025.
• Regulatory Hurdles: This is the most critical factor for the company’s value. They are currently navigating the FDA review process for their "MEDIFLY" products and plan to submit additional data in May 2026. Success here is essential for entering the U.S. market.

4. Financial health

The company is in a high-cost, pre-profit state. Management expects to continue operating at a loss for the foreseeable future. Their survival depends on achieving regulatory approval and successfully scaling product sales to hospitals. If they exhaust their current cash reserves before becoming self-sustaining, they may need to raise more capital, which could involve issuing more shares and diluting current ownership.

5. Key risks

• Regulatory "Red Tape": The medical device industry is strictly regulated. Any delay or denial from the FDA would stall their growth plans and impact the return on their research investments.
• Competition: Cuprina competes against established medical manufacturers with significantly more capital, deeper distribution networks, and greater market experience.
• Cybersecurity: As a handler of sensitive medical data, the company is a target for cyberattacks. A breach could lead to legal liabilities, fines, and reputational damage.

6. Future outlook

Cuprina is prioritizing global market entry over immediate profitability. Investors should expect continued financial volatility until the company can generate sufficient revenue to cover its high operating costs.

Investor Takeaway: Cuprina is a high-risk, high-reward play. Your investment thesis should focus on their ability to navigate the FDA approval process and successfully commercialize their MDT products. If you are considering an investment, keep a close eye on their cash runway and the outcome of their May 2026 FDA data submission.